User:Mr. Ibrahem/Ripretinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ripretinib
Clinical data
Pronunciationrip re' ti nib
Trade namesQinlock
Other namesDCC-2618
AHFS/Drugs.comMonograph
MedlinePlusa620035
License data
Pregnancy
category
  • AU: D[1]
  • Use should be avoided
Routes of
administration		By mouth
Drug classKinase inhibitor[2]
Legal status
Legal status
Identifiers
  • 3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea
Chemical and physical data
FormulaC24H21BrFN5O2
Molar mass510.367 g·mol−1
3D model (JSmol)
  • CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
  • InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
  • Key:CEFJVGZHQAGLHS-UHFFFAOYSA-N

Ripretinib, sold under the brand name Qinlock, is a medication used to treat gastrointestinal stromal tumor (GIST).[4] It is used in cases that have failed at least 3 other treatments.[4] It is taken by mouth.[4]

Common side effects include hair loss, tiredness, nausea, abdominal pain, constipation, muscle pain, diarrhea, and a rash of the palms and soles known as palmar-plantar erythrodysesthesia syndrome.[2] Other side effects may include skin cancer and poor wound healing.[2] Use during pregnancy may harm the baby.[2] It is a kinase inhibitor.[2]

Ripretinib was approved for medical use in Australia and the United States in 2020.[1][4] In the United States it costs about 35,000 per month as of 2021.[5] As of 2021 approval is pending in Europe.[6]

References[edit]

  1. ^ a b c "Qinlock Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 21 July 2020. Archived from the original on 13 August 2020. Retrieved 17 August 2020.
  2. ^ a b c d e f g "DailyMed - QINLOCK- ripretinib tablet". dailymed.nlm.nih.gov. Archived from the original on 28 February 2021. Retrieved 18 October 2021.
  3. ^ "FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors". U.S. Food and Drug Administration (FDA) (Press release). 15 May 2020. Archived from the original on 15 May 2020. Retrieved 15 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b c d e f "Ripretinib Monograph for Professionals". Drugs.com. Archived from the original on 27 November 2020. Retrieved 18 October 2021.
  5. ^ "Qinlock Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 November 2021. Retrieved 18 October 2021.
  6. ^ "Ripretinib". SPS - Specialist Pharmacy Service. 26 February 2019. Archived from the original on 18 October 2021. Retrieved 18 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ripretinib&oldid=1194440484"